How long does ETH-CAT last?

The total duration of ETH-CAT via insufflated is 2 hours to 3 hours. Onset typically occurs within 1 minutes to 5 minutes. Peak effects last 1 hour to 1.5 hours.

ETH-CAT — SubstanceWiki

ETH-CAT

Cathinone · Stimulants

8 dangerous interactions — combining ETH-CAT with certain substances may be life-threatening.

See all

Stimulants(Cathinone)

Quick Dosage

insufflated35–70 mg (common)

oral150–225 mg (common)

Total duration (insufflated)2hr–3hr

View full details

Ethcathinone (ETH-CAT, N-ethylcathinone) is a synthetic stimulant of the cathinone chemical class, structurally derived from cathinone — the principal active alkaloid in khat (Catha edulis) — through N-ethyl substitution. It is the N-ethyl analog of cathinone itself and an N-alkyl homolog of methcathinone, placing it among the simplest and most structurally straightforward members of the synthetic cathinone family.

ETH-CAT acts primarily as a dopamine and norepinephrine reuptake inhibitor, producing stimulant effects qualitatively similar to methcathinone and related compounds but generally considered to be of moderate potency within the cathinone class. The subjective experience is predominantly stimulant in character — increased energy, focus, mild euphoria, appetite suppression, and elevated heart rate — with limited entactogenic component, reflecting its minimal serotonergic activity. Users characterize ETH-CAT as a relatively "clean" cathinone stimulant with a relatively modest risk profile compared to high-potency pyrrolidine cathinones, though this comparison must be made carefully given the limited human research data available.

The primary risks of ETH-CAT are consistent with other cathinone stimulants: cardiovascular stress, compulsive redosing potential (though less severe than pyrrolidine cathinones), sleep disruption, and anxiety at higher doses. Community experience suggests ETH-CAT occupies a middle ground in the cathinone spectrum — not as compelling or intense as A-PVP or MDPV, but more potent and stimulant-directed than entactogenic cathinones like butylone. This positioning means it shares risks with both classes without the specific distinctive features of either.

ETH-CAT is substantially understudied relative to its use prevalence, and the absence of formal pharmacological characterization means that extrapolation from structurally related cathinones is the primary basis for harm reduction guidance.

How It Feels

ETH-CAT, or ethcathinone, arrives with the brisk, no-nonsense onset typical of cathinone stimulants. Within fifteen to thirty minutes of insufflation or thirty to sixty minutes orally, a wave of alert energy begins to build. The mood lifts measurably. There is a subtle but genuine warmth in the chest and a desire to engage, to talk, to move, to do something. The stimulation is moderate in intensity, lacking the overwhelming rush of more potent cathinones but offering a clean, sociable energy that fits easily into everyday contexts.

At the peak, which settles in around forty-five minutes to an hour after onset, the experience is characterized by a gentle euphoria and increased sociability. Conversation flows more readily, social anxiety recedes, and there is a mild empathogenic quality that makes interactions feel warmer and more genuine than usual. The mind is alert and engaged without being frantic. Physical energy increases, and there is a desire to move, though not the compulsive restlessness that accompanies stronger stimulants. Music sounds better. The world feels marginally brighter and more interesting.

The body shows the standard signs of cathinone stimulation. Heart rate is elevated, pupils are somewhat dilated, and appetite is suppressed. There may be mild jaw tension and a slight dryness of the mouth. Body temperature rises marginally, and a light sweat may appear during physical activity. The overall physical load is light, and most users report feeling comfortable and functional throughout. Higher doses intensify the stimulation without proportionally increasing the euphoria, tipping the balance toward uncomfortable side effects.

The duration is relatively short, with the primary effects lasting two to four hours before a gentle taper back to baseline. The comedown is mild by cathinone standards, producing a slight tiredness and a subtle emotional flatness that resolves within a few hours. Sleep is usually achievable within four to six hours of the last dose. The overall impression is of a modest, serviceable stimulant that offers a pleasant social boost without the intensity, duration, or punishing aftermath of its more potent relatives. It is the kind of substance that may leave the user wondering whether the experience was strong enough to justify having taken anything at all.

Detection Methods

Standard Drug Panel Inclusion

Ethcathinone is a substituted cathinone (synthetic cathinone) that is not included on standard 5-panel or 10-panel immunoassay drug screens. Some extended panels (particularly those marketed for "bath salts" detection) may include cross-reactive antibodies for the cathinone class, but coverage is inconsistent. The structural relationship to amphetamine means some cathinones trigger the amphetamine channel on immunoassays, but this is compound-specific and unreliable for Ethcathinone.

Urine Detection

Ethcathinone and its metabolites can typically be detected in urine for 2 to 4 days following a single dose. Repeated or binge-pattern use may extend this window to 5 or more days. Primary metabolic pathways involve reduction of the beta-keto group, N-dealkylation, and hydroxylation. The resulting metabolites are excreted renally, often as glucuronide or sulfate conjugates.

Blood and Saliva Detection

Blood detection windows for Ethcathinone range from 12 to 48 hours depending on dose and individual metabolism. Plasma concentrations decline rapidly due to extensive distribution into tissues. Oral fluid testing can detect Ethcathinone for approximately 24 to 48 hours but is not commonly deployed for synthetic cathinones outside of specialized forensic settings.

Hair Follicle Detection

Hair analysis can detect synthetic cathinones including Ethcathinone for up to 90 days. Incorporation into the hair shaft follows standard pharmacokinetic principles for basic amines. However, most commercial hair testing panels do not specifically target Ethcathinone, requiring custom LC-MS/MS methods with appropriate reference standards.

Confirmatory Testing

Definitive identification of Ethcathinone requires instrumental analysis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for synthetic cathinones due to their thermal lability, which can cause degradation during gas chromatography. GC-MS remains usable but may require derivatization for optimal sensitivity. Reference standards specific to Ethcathinone are necessary for quantitative confirmation.

Reagent Testing

Marquis reagent typically produces no reaction or a faint yellow-orange color with Ethcathinone. Mecke reagent may show no significant color change. Mandelin reagent can produce a yellow to brown reaction. The lack of strong, characteristic color reactions with common reagents makes cathinone identification by reagent testing alone unreliable. A combination of Marquis, Mecke, Mandelin, and Simon's reagents can help rule out other substance classes but cannot positively confirm Ethcathinone.

Interactions

Substance	Status	Note
25x-NBOH	Dangerous	—
25x-NBOMe	Dangerous	—
Atropa belladonna	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Datura	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Diphenhydramine	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Harmala alkaloid	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Peganum harmala	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
MDMA	Unsafe	—
1,3-Butanediol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
25E-NBOH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-2	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-21	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-7	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increased cardiovascular strain and neurotoxicity risk
4-MMC	Caution	Increased cardiovascular strain and neurotoxicity risk
8-Chlorotheophylline	Caution	Increased cardiovascular strain and neurotoxicity risk
Adrafinil	Caution	Increased cardiovascular strain and neurotoxicity risk
Allylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ayahuasca	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Benzydamine	Caution	Increased cardiovascular strain and neurotoxicity risk
Bromantane	Caution	Increased cardiovascular strain and neurotoxicity risk
Cake	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Deschloroetizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Desomorphine	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
DET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increased cardiovascular strain and neurotoxicity risk
Diclazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
DiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DOM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Efavirenz	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephedrine	Caution	Increased cardiovascular strain and neurotoxicity risk
EPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Eszopiclone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Etizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Gaboxadol	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Hexedrone	Caution	Increased cardiovascular strain and neurotoxicity risk
Ibogaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lorazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Mephenaqualone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methallylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increased cardiovascular strain and neurotoxicity risk
Metizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Midazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Naloxone	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
Nicotine	Caution	Increased cardiovascular strain and neurotoxicity risk
Nifoxipam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Oxiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Pentobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenylpiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Psilocybin Mushrooms	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increased cardiovascular strain and neurotoxicity risk
SAMe	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Alcohol	Uncertain	—

Showing 63 key interactions out of 64 total.

Toxicity & Safety

Cardiovascular Effects

ETH-CAT produces sympathomimetic cardiovascular effects through dopamine and norepinephrine reuptake inhibition: elevated heart rate, increased blood pressure, peripheral vasoconstriction. While the potency of these effects is believed to be moderate compared to high-potency pyrrolidine cathinones, they are dose-dependent and represent meaningful risk at higher doses or in individuals with pre-existing cardiovascular disease.

Compulsive Use Risk

While ETH-CAT is likely less compulsively driven than high-potency pyrrolidine cathinones (A-PVP, MDPV), the cathinone dopaminergic mechanism carries inherent reinforcing properties. The short-to-moderate duration of effects (2–4 hours) and the hedonic appeal of the stimulant effects create conditions for repeated dosing. Community accounts of cathinone comedowns apply to ETH-CAT — fatigue, dysphoria, and disrupted sleep follow extended use.

Psychiatric Effects

High-dose or extended use may produce anxiety, paranoia, and in extreme cases stimulant psychosis, consistent with other dopaminergic stimulants. This risk is substantially lower with ETH-CAT than with high-potency pyrrolidine cathinones but is not absent.

Unknown Risks

The limited formal research on ETH-CAT means that the full toxicological profile — particularly chronic and neurotoxic effects — is unknown. This uncertainty itself constitutes a significant risk.

Drug Interactions

MAOIs: Contraindicated — risk of hypertensive crisis
Other stimulants: Additive cardiovascular strain
Alcohol: Masks stimulant toxicity warning signs

Addiction Potential

mildly addictive with a comparatively low potential for abuse

Overdose Information

Stimulant overdose from ETH-CAT is a medical emergency primarily involving cardiovascular and neurological toxicity.

Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.Emergency response:

Call emergency services immediately
Keep the person cool (remove excess clothing, apply cool water)
If seizures occur, protect the head and clear the area of hard objects
If the person loses consciousness, place in recovery position
Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionalsPrevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.

Full	develops with prolonged and repeated use
Half	2 - 3 days
Zero	3-5 days

ETH-CAT

Quick Dosage

Dosage

insufflated

oral

Duration

insufflated

oral

How It Feels

Subjective Effects

Physical Effects

Physical(2)

Cognitive & Perceptual Effects

Cognitive(6)

Pharmacology

Mechanism of Action

Relative Activity at Monoamine Transporters

Pharmacokinetics

Comparisons

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Saliva Detection

Hair Follicle Detection

Confirmatory Testing

Reagent Testing

Interactions

History

Chemical Background

Appearance in NPS Markets

Regulatory Status

Research Context

Harm Reduction

Test Your Substance

Dose Carefully

Avoid Compulsive Redosing

Dangerous Combinations

Research the Specific Batch

Toxicity & Safety

Cardiovascular Effects

Compulsive Use Risk

Psychiatric Effects

Unknown Risks

Drug Interactions

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (3)

See Also

References (5)

Frequently Asked Questions